These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 32359104

  • 1. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
    Higuchi S, Takahashi M, Murai Y, Tsuneyoshi K, Nakamura I, Meulien D, Miyata H.
    Psychiatry Clin Neurosci; 2020 Aug; 74(8):431-438. PubMed ID: 32359104
    [Abstract] [Full Text] [Related]

  • 2. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R.
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [Abstract] [Full Text] [Related]

  • 3. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K, Bladström A, Torup L, Gual A, van den Brink W.
    Biol Psychiatry; 2013 Apr 15; 73(8):706-13. PubMed ID: 23237314
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
    van den Brink W, Sørensen P, Torup L, Mann K, Gual A, SENSE Study Group.
    J Psychopharmacol; 2014 Aug 15; 28(8):733-44. PubMed ID: 24671340
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Pharmacological profile and clinical findings of nalmefene (Selincro®) for reducing alcohol consumption in patients with alcohol dependence].
    Tadori Y.
    Nihon Yakurigaku Zasshi; 2020 Aug 15; 155(2):113-119. PubMed ID: 32115477
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.
    van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K.
    Alcohol Alcohol; 2013 Aug 15; 48(5):570-8. PubMed ID: 23873853
    [Abstract] [Full Text] [Related]

  • 10. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
    Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.
    Clin Drug Investig; 2018 Feb 15; 38(2):147-155. PubMed ID: 29080208
    [Abstract] [Full Text] [Related]

  • 11. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun 15; 23(150):150-2. PubMed ID: 25121147
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
    van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K.
    Expert Opin Drug Saf; 2015 Apr 15; 14(4):495-504. PubMed ID: 25652768
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
    Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.
    Alcohol Clin Exp Res; 1994 Oct 15; 18(5):1162-7. PubMed ID: 7847600
    [Abstract] [Full Text] [Related]

  • 14. Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
    Mueller S, Luderer M, Zhang D, Meulien D, Brach BS, Schou MB.
    Alcohol Alcohol; 2020 Feb 07; 55(1):63-70. PubMed ID: 31713583
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M, Friede M, Schnitker J.
    Pharmacopsychiatry; 2016 Mar 07; 49(2):66-75. PubMed ID: 26845589
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB.
    Arch Gen Psychiatry; 1999 Aug 07; 56(8):719-24. PubMed ID: 10435606
    [Abstract] [Full Text] [Related]

  • 18. Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.
    Castera P, Stewart E, Großkopf J, Brotons C, Brix Schou M, Zhang D, Steiniger Brach B, Meulien D, on behalf of the PICASO Study Investigators.
    Eur Addict Res; 2018 Aug 07; 24(6):293-303. PubMed ID: 30485854
    [Abstract] [Full Text] [Related]

  • 19. Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
    Milano G, Zavan V, Natta WM, Martelli A, Mattioli F.
    J Clin Pharm Ther; 2016 Feb 07; 41(1):97-100. PubMed ID: 26714742
    [Abstract] [Full Text] [Related]

  • 20. Safety of nalmefene for the treatment of alcohol use disorder: an update.
    López-Pelayo H, Zuluaga P, Caballeria E, Van den Brink W, Mann K, Gual A.
    Expert Opin Drug Saf; 2020 Jan 07; 19(1):9-17. PubMed ID: 31868031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.